ArticleHaematologica2025

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy.

Isla M Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.